
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …

The coming year is set to see mergers and acquisitions in the healthcare sector worth more than $400 billion, according …

Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …

One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …
Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …

Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …

Merck KGaA has announced the completion of its $17 billion acquisition of Sigma-Aldrich, having cleared the final regulatory hurdle and …

LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …

AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …